Imunon, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
IMNN$0.88+4.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $8,781,059 | $5,872,767 |
| Advances and deposits on clinical programs and other current assets | 1,942,685 | 2,136,192 |
| Total current assets | 10,723,744 | 8,008,959 |
| Property and equipment (at cost, less accumulated depreciation and amortization) | 529,936 | 541,272 |
| Other assets: | ||
| Operating lease right-of-use assets, net | 984,436 | 1,117,133 |
| Deposits and other assets | 50,000 | 50,000 |
| Total other assets | 1,034,436 | 1,167,133 |
| Total assets | $12,288,116 | $9,717,364 |
CONSOLIDATED BALANCE SHEETS
(Continued)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable – trade | $1,392,829 | $1,300,026 |
| Other accrued liabilities | 2,824,646 | 3,033,747 |
| Operating lease liabilities - current portion | 406,354 | 452,358 |
| Total current liabilities | 4,623,829 | 4,786,131 |
| Operating lease liabilities - non-current portion | 602,411 | 686,935 |
| Total liabilities | 5,226,240 | 5,473,066 |
| Commitments and contingencies | – | – |
| Stockholders’ equity: | ||
| Preferred Stock - $0.01 par value (100,000 shares authorized, and no shares issued or outstanding at December 31, 2025 and 2024) | – | – |
| Common stock - $0.01 par value (350,000,000 and 112,500,000 shares authorized at December 31, 2025 and 2024, respectively; 3,419,652 and 966,714 shares issued at December 31, 2025 and 2024, respectively, and 3,419,650 and 966,712 shares outstanding at December 31, 2025 and 2024, respectively) | 34,197 | 9,667 |
| Additional paid-in capital | 428,410,939 | 411,122,863 |
| Accumulated deficit | (421,298,072) | (406,803,044) |
| Total stockholders’ equity before treasury stock | 7,147,064 | 4,329,486 |
| Treasury stock, at cost (2 shares at December 31, 2025 and 2024) | (85,188) | (85,188) |
| Total stockholders’ equity | 7,061,876 | 4,244,298 |
| Total liabilities and stockholders’ equity | $12,288,116 | $9,717,364 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.